Altis’ mission is to provide scientific innovation, through collaborative relationships, by helping companies develop safer and more effective therapies to treat patients suffering from human disease. We support life science researchers by providing expertise and unique in vitro platforms to further their research and increase their understanding of human biology, while reducing the need for animal testing. Altis Biosystems has pioneered the creation of Repligut® Systems, a collection of in vitro models derived from stem cells and designed specifically for pre-clinical drug discovery. These innovative systems overcome the constraints of conventional cell lines and animal models, providing a highly accurate representation of human intestinal physiology. Our flagship RepliGut® Planar models advance novel pharmaceuticals by harnessing the potential of human donor intestinal stem cells. These cells undergo a process of sequential proliferation and differentiation, ultimately transforming into the essential cell types found in the human gastrointestinal epithelium for use in drug discovery and development. Our RepliGut® Models, which accurately replicate the complex cellular lifecycle of the intestinal crypt, provide an exceptional platform for numerous applications. Derived from various regions of the intestine, they allow for compound screening, disease modeling, drug disposition analysis, toxicity assessments, efficacy studies, and fundamental research investigations. With their human-derived physiologically-relevant capabilities, our models have the power to vastly reduce the dependence on animal studies, in line with the transforming landscape of pre-clinical drug discovery.